ORGANIC
LETTERS
XXXX
Vol. XX, No. XX
000–000
Total Synthesis of the Tetracyclic Lupin
Alkaloid (þ)-Allomatrine
Samuel V. Watkin,† Nicholas P. Camp,‡ and Richard C. D. Brown*,†
Department of Chemistry, The University of Southampton, Highfield, Southampton
SO17 1BJ, U.K., and Eli Lilly Research Centre U.K., Erl Wood Manor,
Windlesham GU20 6PH, U.K.
Received August 2, 2013
ABSTRACT
(þ)-Allomatrine (1) has been synthesized using an imino-aldol reaction and N-acyliminium cyclization as key steps. Strategically, use of the
tert-butylsulfinimine derivative of (E)-4-(trimethylsilyl)but-2-enal enabled the staged formation of three CꢀC bonds, a CꢀN bond, and the four
stereogenic centers within the target.
(þ)-Allomatrine (1) is a tetracyclic lupin alkaloid of the
matrine structural class (Figure 1) first reported in 1952 as
a product of chemical epimerization of (þ)-matrine (2)
at C6.1ꢀ3 While (þ)-matrine (2) was obtained from the
root bark of Sophora flavescens by Nagai as early as 1889,4
(þ)-allomatrine has only recently been reported as a
chemicalcomponent from the Sophora species.5 Curiously,
Orechoff isolated an alkaloid, (ꢀ)-leontine (3),6 from
Leontice eversmanni Bge. in the 1930s that was later shown
to be the enantiomer of (þ)-allomatrine (1).7 Matrine (2)
and its related alkaloids exhibit a variety of interesting
biological activities such as anticancer, promotion of hair
growth, and antiviral activity.5b,8 Notably, (þ)-allomatrine
(1) mediates antinociception in mice through selective
activity at the κ-opioid receptor while being structurally
distinct from known pharmacological agents.9
Three total syntheses of racemic matrine have been
accomplished with varying levels of diastereocontrol,10ꢀ12
and a mixture enriched in (()-allomatrine ((()-leontine) was
obtained by Mandell and co-workers from Pd-catalyzed
† The University of Southampton.
‡ Eli Lilly Research Centre U.K.
(1) Isomerization of (þ)-matrine to (þ)-allomatrine: Ochiai, E.;
Okuda, S.; Minato, H. Yakugaku Zasshi. 1952, 72, 781–784.
(2) Structural and stereochemical elucidation: (a) Bohlmann, F.;
Weise, W.; Rahtz, D.; Arndt, C. Chem. Ber. 1958, 91, 2176–2189. (b)
Tsuda, K.; Mishima, H. J. Org. Chem. 1958, 23, 1179–1183. X-ray
structure: (c) Ibragimov, B. T.; Tishenko, G. N.; Kushmuradov, Y. K.;
Aripov, T. F.; Sadikov, A. S. Khim. Prir. Soedin. 1979, 416–417.
Absolute stereochemistry (inferred from 11R configuration in
(þ)-matrine): (d) Okuda, S.; Yoshimoto, M.; Tsuda, K.; Utzugi, N.
Chem. Pharm. Bull. 1966, 14, 314–318.
(3) For a review of lupin alkaloids, see: (a) Ohmiya, S.; Saito, K.;
Murakoshi, I. In The Alkaloids: Chemistry and Pharmacology; Cordell,
G. A., Ed.; Academic Press: New York, 1995; Vol. 47, pp 1ꢀ114. For the
most recent in a series of reviews of quinolizidine alkaloids, see:
(b) Michael, J. P. Nat. Prod. Rep. 2008, 25, 139–165.
(6) Orechoff, A.; Konowalowa, R. Arch. Pharm. 1932, 270, 329–334.
(7) Rulko, F.; Proskurnina, N. F. Zh. Obshch. Khim. 1961, 31, 308–
313.
(8) For examples, see: (a) Ma, L. D.; Wen, S. H.; Zhan, Y.; He, Y. J.;
Uu, X. S.; Jiang, J. K. Planta Med. 2008, 74, 245–251. (b) Roh, S.-S.;
Kim, C. D.; Lee, M.-H.; Hwang, S.-L.; Rang, M.-J.; Yoon, Y.-K. Derm.
Sci. 2002, 30, 43–49. (c) Gao, L. M.; Han, Y. X.; Wang, Y. P.; Li, Y. H.;
Shan, Y. Q.; Li, X.; Peng, Z. G.; Bi, C. W.; Zhang, T. A.; Du, N. N.;
Jiang, J. D.; Song, D. Q. J. Med. Chem. 2011, 54, 869–876.
(9) Higashiyama, K.; Takeuchi, Y.; Yamauchi, T.; Imai, S.; Kamei,
J.; Yajima, Y.; Narita, M.; Suzuki, T. Biol. Pharm. Bull. 2005, 28, 845–
848.
(10) Mandell, L.; Singh, K. P.; Gresham, J. T.; Freeman, W. J. J. Am.
Chem. Soc. 1965, 87, 5234–5236.
(11) Chen, J.; Browne, L. J.; Gonnela, N. C. J. Chem. Soc., Chem.
Commun. 1986, 905–907.
(12) Boiteau, L.; Boivin, J.; Liard, A.; Quiclet-Sire, B.; Zard, S. Z.
Angew. Chem., Int. Ed. 1998, 37, 1128–1131.
(4) Nagai, N. Yakugaku Zasshi 1889, 9, 54–87.
(5) Allomatrine is described as a natural product in previous pub-
lications; however, these papers give reference to isomerized matrine or
personal communications. For isolation of (þ)-allomatrine Sophora
species, see: (a) Xiao, P.; Li, J.; Kubo, H.; Saito, K.; Murakoshi, I.;
Ohmiya, S. Chem. Pharm. Bull. 1996, 44, 1951–1953. (b) Ding, P.-L.;
Liao, Z.-X.; Huang, H.; Zhou, P.; Chen, D.-F. Bioorg. Med. Chem. Lett.
2006, 16, 1231–1235. (c) Liu, X.-J.; Cao, M.-A.; Li, W.-H.; Shen, C.-S.;
Yan, S.-Q.; Yuan, C.-S. Fitoterapia 2010, 81, 524–527.
r
10.1021/ol402198n
XXXX American Chemical Society